AptarGroup (ATR)
(Delayed Data from NYSE)
$146.81 USD
+0.89 (0.61%)
Updated May 3, 2024 04:00 PM ET
After-Market: $146.82 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
ATR 146.81 +0.89(0.61%)
Will ATR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ATR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATR
Sealed Air (SEE) Q1 Earnings Top Estimates, Increase Y/Y
Crown Holdings (CCK) Q1 Earnings Beat, Sales Lag Estimates
ATR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amcor (AMCR) Q3 Earnings Beat, Revenues Dip Y/Y on Low Volumes
O-I Glass (OI) Beats Q1 Earnings Estimates, Lowers '24 Outlook
All You Need to Know About AptarGroup (ATR) Rating Upgrade to Buy
Other News for ATR
UK dividends calendar
UK dividends calendar - next 7 days
Insider Sale at AptarGroup Inc: Segment President Hedi Tlili Sells 4,634 Shares
Silgan Holdings: Earnings Are Proof That There Are Better Prospects Out There
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)